RZ Nomics

Rewriting the Future of RNA Therapy

Yongin, South Korea · Founded 2017 · $30.0M raised

Headquarters
Yongin
Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$30.0M
Last Round
$30.0M Series CJan 2023
Rounds
1

About

Rznomics Inc. (standing for Ribozyme and Omics) is a South Korean biopharmaceutical company founded in 2017 by Professor Seong-Wook Lee at Dankook University, Yongin, South Korea. The company develops RNA-based gene therapies targeting oncology, degenerative diseases, and genetic diseases using its proprietary trans-splicing ribozyme RNA platform. Rznomics has attracted significant partnerships, including a $1.3 billion out-licensing deal with Eli Lilly focused on RNA editing for hearing loss, and is preparing for a Kosdaq IPO.

Summary

RZ Nomics is a Biotech company based in Yongin, South Korea, founded in 2017. It has raised $30.0M in total across 1 round, most recently a $30.0M Series C round in Jan 2023. Investors include SBI Investment Korea and Korean Development Bank.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CJan 2023
$30.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

RZ Nomics on Indexed.vc
<a href="https://indexed.vc/companies/rz-nomics"><img src="https://indexed.vc/api/badge/company/rz-nomics" alt="RZ Nomics on Indexed.vc" width="260" height="76" /></a>